People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The purpose of this research is to determine if zasocitinib works better than deucravacitinib in treating moderate-to-severe plaque psoriasis. The study will specifically look at how well these medications clear the skin condition by measuring improvements in the affected areas of skin and the severity of psoriasis symptoms.

During the 16-week study period, participants will take their assigned medication by mouth once each day. The effectiveness of the treatment will be evaluated by examining changes in the skin’s appearance and measuring the reduction in psoriasis symptoms. Throughout the study, doctors will monitor participants’ health and safety through regular check-ups, including physical examinations and laboratory tests.

The study involves taking either TAK-279, apremilast, or placebo in the form of tablets that are swallowed. During the study, doctors will monitor how well the medications work by examining changes in the skin’s appearance and the extent of psoriasis coverage on the body. They will look at improvements in skin clearance and reduction in psoriasis symptoms.

The research will include periods where some participants may switch between different treatments to better understand how the medication works over time. The study will track various aspects of psoriasis, including how it affects the scalp, nails, hands, and feet. Participants will be monitored for approximately 60 weeks to evaluate both the effectiveness and safety of the treatment.

Participants in the study will receive ESK-001, which is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The treatment period can last up to 48 weeks, and the study will monitor how patients respond to the medication over this time. The goal is to see if ESK-001 can help reduce the symptoms of plaque psoriasis and maintain these improvements.

The study will also look at the quality of life of participants, assessing changes in their daily living and comfort levels. By the end of the study, researchers hope to gather valuable information on the long-term use of ESK-001 for treating moderate to severe plaque psoriasis, which could help in managing the condition more effectively in the future.

The purpose of the study is to determine if ESK-001 is more effective than a placebo after 16 weeks of treatment. Participants will be randomly assigned to receive either ESK-001, Otezla, or a placebo. The study will last up to 24 weeks, during which participants will take the medication orally. The trial aims to see improvements in the skin condition by measuring changes in the severity and extent of the psoriasis patches.

Throughout the study, participants will be monitored to assess the safety and effectiveness of the treatments. The trial will help researchers understand if ESK-001 can provide better outcomes for people with moderate to severe plaque psoriasis compared to existing treatments. This study is an important step in finding new and effective ways to manage this chronic skin condition.

Participants in the study will take Zasocitinib in the form of a film-coated tablet, which is taken orally once a day. The study will monitor participants over a period of time to observe any side effects or changes in their condition. The study aims to see if the medication can help improve the symptoms of plaque psoriasis, such as reducing the size and severity of the skin patches.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur while taking the medication. They will also look for improvements in the condition, such as a significant reduction in the psoriasis area and severity. The study is designed to provide valuable information about the long-term use of Zasocitinib for treating moderate-to-severe plaque psoriasis.

The purpose of this study is to see if the combination of gliclazide MR and dapagliflozin, with or without metformin, is better at reducing blood sugar levels compared to a placebo and dapagliflozin, with or without metformin. Participants in the study will be randomly assigned to receive either the combination of medications or a placebo. The study will last for 24 weeks, during which participants will take the medications by mouth as tablets. Throughout the study, participants will have regular check-ups to monitor their blood sugar levels and overall health.

By the end of the study, researchers aim to determine if the combination of gliclazide MR and dapagliflozin, with or without metformin, is more effective in lowering blood sugar levels than the current treatment options. This information could help improve treatment strategies for people with Type 2 Diabetes who are not achieving optimal blood sugar control with their current medications.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

Participants in the study will be randomly assigned to receive either asundexian or apixaban. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of up to 33 days, during which the safety and effectiveness of the treatments will be closely monitored.

The main goal is to see if asundexian is at least as effective as apixaban in preventing stroke and systemic embolism, and to assess the risk of major bleeding, which is a significant concern with blood-thinning medications. The study will also look at other outcomes, such as the occurrence of minor bleeding, cardiovascular events, and overall mortality. This research aims to provide valuable information on the potential benefits and risks of asundexian compared to apixaban for people with atrial fibrillation at risk of stroke.

The purpose of the study is to determine if Inclisiran can reduce the risk of serious heart problems, such as heart attacks, strokes, or the need for urgent procedures to restore blood flow to the heart. The study will be conducted over a period of time, during which participants will receive regular injections of the medication or placebo and will be monitored for any heart-related events. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants will be closely observed throughout the study to track the time it takes for any major heart events to occur. The study will also look at other outcomes, such as the time to cardiovascular death and overall mortality. The goal is to gather information on the safety and effectiveness of Inclisiran in preventing heart-related issues in people who are at high risk but have not yet had a major cardiovascular event.